A
Anna Katharina Winge-Main
Publications - 1
Citations - 185
Anna Katharina Winge-Main is an academic researcher. The author has contributed to research in topics: Adjuvant therapy & Pembrolizumab. The author has an hindex of 1, co-authored 1 publications receiving 18 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alex Menzies,Thierry Lesimple,Michele Maio,Gerald P. Linette,Michael C. Brown,Peter Hersey,Inge Marie Svane,Laurent Mortier,Jacob Schachter,Catherine Barrow,Ragini R. Kudchadkar,Xinni Song,Caroline Dutriaux,Pietro Quaglino,Friedegund Meier,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Bernard Guillot,Claus Garbe,Pablo Luis Ortiz Romero,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Jean-Philippe Arnault,Philippe Saiag,Carmen Loquai,Frank Meiss,Jan-Christoph Simon,Gil Bar-Sela,Vanna Chiarion Sileni,Bernard Fitzharris,Mike McCrystal,Phillip Parente,Jean-Francois Baurain,Patrick Combemale,Céleste Lebbé,Axel Hauschild,Naoya Yamazaki,Reinhard Dummer,Mohammed M. Milhem,Marcin Dzienis,John Walker,Lionel Geoffrois,Marie-Thérèse Leccia,Lutz Kretschmer,Daniel Hendler,Michal Lotem,Andrzej Mackiewicz,Lidija Sekulovic,Elaine Dunwoodie,Christoph Hoeller,Laurent Machet,Jessica C. Hassel,Geke A. P. Hospers,Maria-Jose Passos,Max Levin,Martin Fehr,Philippa Corrie,Ashita Waterston,Sigrun Hallmeyer,Henrik Schmidt,Vincent Descamps,Jean-Philippe Lacour,Carola Berking,Felix Kiecker,Pier Francesco Ferrucci,Kenji Yokota,Maureen J.B. Aarts,Michael B. Jameson,Anna Katharina Winge-Main,Paula Ferreira,Kevin B. Kim,Catriona M. McNeil,Reiner Hofmann-Wellenhof,Joseph Kerger,François Aubin,Jochen Utikal,Virginia Ferraresi,Takashi Inozume,Yoshio Kiyohara,Gerard Groenewegen,Helena Kapiteijn,Suzana Matkovic,Wolf-Henning Boehncke,Richard Casasola,Timothy Crook,Ernest Marshall,Tanja Skytta,Marie-Francoise Avril,Thomas Jouary,Rüdiger Hein,Patrick Terheyden,Jun Aoi,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina,Paul C. Nathan +131 more
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.